Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lance Tigyer

Orthopaedic Surgery of the Spine Dayton, OH Doctor of Osteopathy

NPI 1558320408 CMS profile 342774

7980 N. Main St., Dayton, OH 45415

Open in the dashboard

General payments

$29,072

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$100,000

2 holdings reported · through program year 2025

Through program year 2025, Lance Tigyer of Dayton, OH is reported in the CMS Open Payments database as having received $29,072 across 137 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $100,000 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,891 36
2024 General $797 17
2023 General $789 13
2022 General $5,485 15
2021 General $1,905 23
2020 General $1,273 11
2019 General $16,933 22
2022 Ownership $50,000 1
2021 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Tigyer
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Lance Tigyer were reported at $1,891. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Lance Tigyer Orthopaedic Surgery of the Spine median Middle half National median
2019 $16,933 $2,106 $337–$18,608 $163
2020 $1,273 $1,213 $156–$15,082 $114
2021 $1,905 $1,834 $271–$15,617 $132
2022 $5,485 $2,015 $320–$17,036 $149
2023 $789 $1,925 $336–$14,599 $160
2024 $797 $2,110 $341–$12,483 $164
2025 $1,891 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $16,530 23 payments
  2. CTL Medical Corporation $6,168 9 payments
  3. Boston Scientific Corporation $1,637 47 payments
  4. Centinel Spine, LLC $1,593 4 payments
  5. Integrity Implants Inc $1,052 3 payments
  6. Abbott Laboratories $975 19 payments
  7. Nevro Corp. $207 7 payments
  8. Camber Spine Technologies $156 2 payments
  9. Zimvie Inc. $148 1 payment
  10. Elevation Spine, Inc. $117 1 payment
  11. Other $489 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $18,984 15 payments
  2. Food and Beverage $5,742 118 payments
  3. Consulting Fee $3,900 2 payments
  4. Gift $447 2 payments
Products named General payments · program years 2019–2025
  1. MYSPINE $16,091 18 payments
  2. Spinal $5,859 7 payments
  3. PRODISC C $1,113 2 payments
  4. PRODISC L $480 2 payments
  5. Artisan $469 8 payments
  6. MECTALIF $310 4 payments
  7. PROCLAIM Structural Heart $284 3 payments
  8. Raphael Pedicle Screw System $240 1 payment
  9. Proclaim IPG $204 8 payments
  10. PROCLAIM Neuromodulation $179 2 payments
  11. Other $2,279 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

248

Median for Orthopedic Surgery: 203

Drug cost

$1,621

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 89 $779
Doxycycline Hyclate Generic 52 $331
Tizanidine Hcl Generic 32 $231
Methocarbamol Generic 14 $200
Ibuprofen Generic 18 $42
Diazepam Generic 43 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$375,879

Of which drugs: $1,164

Medicare patients

476

Average age 75

Services billed

4,403

270 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 33%
Depression 31%
Chronic kidney disease 27%
COPD 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 89 1,408 $1,074
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 266 998 $90

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $11
$11 — —
Prolia
  • Amgen Inc. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record